Please enable JavaScript to continue using this application.

Compare $FDMT vs $GYRE | Chartloom

Compare

$FDMT vs $GYRE

4D Molecular Therapeutics Inc · Gyre Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Compare $FDMT vs $GYRE

Comparing 4D Molecular Therapeutics Inc and Gyre Therapeutics Inc

FDMT4D Molecular Therapeutics Inc

GYREGyre Therapeutics Inc

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FDMT

GYRE

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

FDMT$697M

GYRE$643M

Enterprise Value

FDMT$646M

GYRE$600M

Price

FDMT$13.33

GYRE$7.04

P/E Ratio

FDMTN/A

GYREN/A

P/S Ratio

FDMT7.57x

GYRE5.39x

EV/Sales

FDMT7.02x

GYRE5.03x

EV/EBITDA

FDMT0.00x

GYRE286.88x

P/B Ratio

FDMT1.85x

GYRE5.78x

P/FCF Ratio

FDMTN/A

GYREN/A

EV/FCF

FDMT-4.13x

GYRE-35.74x

PEG Ratio

FDMTN/A

GYREN/A

Forward P/E (NTM)

FDMTN/A

GYREN/A

Forward P/S (NTM)

FDMT50.39x

GYREN/A

Revenue (TTM)

FDMT$92M

GYRE$119M

Revenue Growth (YoY)

FDMT278712.1%

GYRE16.8%

Forward Rev Growth

FDMT40.6%

GYRE21.1%

Gross Margin (TTM)

FDMT0.0%

GYRE94.3%

Operating Margin (TTM)

FDMT0.0%

GYRE0.0%

EBITDA Margin (TTM)

FDMT-208.8%

GYRE-8.5%

Net Margin (TTM)

FDMT-194.7%

GYRE-15.5%

FCF Margin (TTM)

FDMT-169.9%

GYRE-14.1%

Net Income (TTM)

FDMT$-179M

GYRE$-18M

FCF (TTM)

FDMT$-156M

GYRE$-17M

EPS (TTM)

FDMT-$2.55

GYRE-$0.18

ROE (TTM)

FDMT-4133.0%

GYRE-1584.0%

ROA (TTM)

FDMT-3590.0%

GYRE-1014.0%

ROIC (TTM)

FDMT-4087.0%

GYRE-1584.0%

Cash

FDMT$70M

GYRE$43M

Debt

FDMT$20M

GYRE$0

Net Cash/Debt

FDMT$51M

GYRE$43M

Current Ratio (TTM)

FDMT8.03x

GYRE4.26x

Quick Ratio (TTM)

FDMT7.68x

GYRE3.64x

Debt/Equity (TTM)

FDMT0.05x

GYRE0.00x

Debt/Assets (TTM)

FDMT0.0%

GYRE0.0%

Interest Coverage (TTM)

FDMTN/A

GYREN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

GYRE0.00x

Beta

FDMT2.90

GYRE2.46

52W Performance

FDMT38.0%

GYRE-3.6%

YTD Performance

FDMT82.1%

GYRE3.4%

% from 52W High

FDMT-21.3%

GYRE-25.3%

% from 52W Low

FDMT91.5%

GYRE29.4%

Asset Turnover (TTM)

FDMT0.18x

GYRE0.70x

FCF Yield (TTM)

FDMT-22.4%

GYRE-2.6%

Earnings Yield (TTM)

FDMT-25.7%

GYRE-2.9%

Dividend Yield (TTM)

FDMTN/A

GYREN/A

Rule of 40

FDMT278,542.3

GYRE2.8

EV/GP/RG

FDMTN/A

GYRE0.23

Ticker research

View FDMT research View GYRE research

Metric	FDMT 4D Molecular Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$697M	$643M
Enterprise Value	$646M	$600M
Price	$13.33	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	5.39x
EV/Sales	7.02x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	1.85x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	N/A
Revenue & Growth
Revenue (TTM)	$92M	$119M
Revenue Growth (YoY)	278712.1%	16.8%
Forward Rev Growth	40.6%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-8.5%
Net Margin (TTM)	-194.7%	-15.5%
FCF Margin (TTM)	-169.9%	-14.1%
Net Income (TTM)	$-179M	$-18M
FCF (TTM)	$-156M	$-17M
EPS (TTM)	-$2.55	-$0.18
ROE (TTM)	-4133.0%	-1584.0%
ROA (TTM)	-3590.0%	-1014.0%
ROIC (TTM)	-4087.0%	-1584.0%
Financial Health
Cash	$70M	$43M
Debt	$20M	$0
Net Cash/Debt	$51M	$43M
Current Ratio (TTM)	8.03x	4.26x
Quick Ratio (TTM)	7.68x	3.64x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	2.46
52W Performance	38.0%	-3.6%
YTD Performance	82.1%	3.4%
% from 52W High	-21.3%	-25.3%
% from 52W Low	91.5%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.70x
FCF Yield (TTM)	-22.4%	-2.6%
Earnings Yield (TTM)	-25.7%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	2.8
EV/GP/RG	N/A	0.23
Ticker research	View FDMT research	View GYRE research

Valuation

P/S Ratio

GYRE

5.39x

FDMT

7.57x

EV/FCF

GYRE

-35.74x

FDMT

-4.13x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

GYRE

16.8%

Forward Revenue Growth

FDMT

40.6%

GYRE

21.1%

Profitability & performance

Gross Margin

GYRE

94.3%

FDMT

0.0%

ROE

GYRE

-1584.0%

FDMT

-4133.0%

FCF Yield %

GYRE

-2.6%

FDMT

-22.4%

52-Week Performance

FDMT

38.0%

GYRE

-3.6%

Detailed metrics comparison

FDMT

4D Molecular Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

FDMT$697M

GYRE$643M

Enterprise Value

FDMT$646M

GYRE$600M

Price

FDMT$13.33

GYRE$7.04

P/E Ratio

FDMTN/A

GYREN/A

P/S Ratio

FDMT7.57x

GYRE5.39x

EV/Sales

FDMT7.02x

GYRE5.03x

EV/EBITDA

FDMT0.00x

GYRE286.88x

P/B Ratio

FDMT1.85x

GYRE5.78x

P/FCF Ratio

FDMTN/A

GYREN/A

EV/FCF

FDMT-4.13x

GYRE-35.74x

PEG Ratio

FDMTN/A

GYREN/A

Forward P/E (NTM)

FDMTN/A

GYREN/A

Forward P/S (NTM)

FDMT50.39x

GYREN/A

Revenue (TTM)

FDMT$92M

GYRE$119M

Revenue Growth (YoY)

FDMT278712.1%

GYRE16.8%

Forward Rev Growth

FDMT40.6%

GYRE21.1%

Gross Margin (TTM)

FDMT0.0%

GYRE94.3%

Operating Margin (TTM)

FDMT0.0%

GYRE0.0%

EBITDA Margin (TTM)

FDMT-208.8%

GYRE-8.5%

Net Margin (TTM)

FDMT-194.7%

GYRE-15.5%

FCF Margin (TTM)

FDMT-169.9%

GYRE-14.1%

Net Income (TTM)

FDMT$-179M

GYRE$-18M

FCF (TTM)

FDMT$-156M

GYRE$-17M

EPS (TTM)

FDMT-$2.55

GYRE-$0.18

ROE (TTM)

FDMT-4133.0%

GYRE-1584.0%

ROA (TTM)

FDMT-3590.0%

GYRE-1014.0%

ROIC (TTM)

FDMT-4087.0%

GYRE-1584.0%

Cash

FDMT$70M

GYRE$43M

Debt

FDMT$20M

GYRE$0

Net Cash/Debt

FDMT$51M

GYRE$43M

Current Ratio (TTM)

FDMT8.03x

GYRE4.26x

Quick Ratio (TTM)

FDMT7.68x

GYRE3.64x

Debt/Equity (TTM)

FDMT0.05x

GYRE0.00x

Debt/Assets (TTM)

FDMT0.0%

GYRE0.0%

Interest Coverage (TTM)

FDMTN/A

GYREN/A

Net Debt/EBITDA (TTM)

FDMT0.00x

GYRE0.00x

Beta

FDMT2.90

GYRE2.46

52W Performance

FDMT38.0%

GYRE-3.6%

YTD Performance

FDMT82.1%

GYRE3.4%

% from 52W High

FDMT-21.3%

GYRE-25.3%

% from 52W Low

FDMT91.5%

GYRE29.4%

Asset Turnover (TTM)

FDMT0.18x

GYRE0.70x

FCF Yield (TTM)

FDMT-22.4%

GYRE-2.6%

Earnings Yield (TTM)

FDMT-25.7%

GYRE-2.9%

Dividend Yield (TTM)

FDMTN/A

GYREN/A

Rule of 40

FDMT278,542.3

GYRE2.8

EV/GP/RG

FDMTN/A

GYRE0.23

Ticker research

View FDMT research View GYRE research

Metric	FDMT 4D Molecular Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$697M	$643M
Enterprise Value	$646M	$600M
Price	$13.33	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	7.57x	5.39x
EV/Sales	7.02x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	1.85x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.13x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	50.39x	N/A
Revenue & Growth
Revenue (TTM)	$92M	$119M
Revenue Growth (YoY)	278712.1%	16.8%
Forward Rev Growth	40.6%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-208.8%	-8.5%
Net Margin (TTM)	-194.7%	-15.5%
FCF Margin (TTM)	-169.9%	-14.1%
Net Income (TTM)	$-179M	$-18M
FCF (TTM)	$-156M	$-17M
EPS (TTM)	-$2.55	-$0.18
ROE (TTM)	-4133.0%	-1584.0%
ROA (TTM)	-3590.0%	-1014.0%
ROIC (TTM)	-4087.0%	-1584.0%
Financial Health
Cash	$70M	$43M
Debt	$20M	$0
Net Cash/Debt	$51M	$43M
Current Ratio (TTM)	8.03x	4.26x
Quick Ratio (TTM)	7.68x	3.64x
Debt/Equity (TTM)	0.05x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.90	2.46
52W Performance	38.0%	-3.6%
YTD Performance	82.1%	3.4%
% from 52W High	-21.3%	-25.3%
% from 52W Low	91.5%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.70x
FCF Yield (TTM)	-22.4%	-2.6%
Earnings Yield (TTM)	-25.7%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	278,542.3	2.8
EV/GP/RG	N/A	0.23
Ticker research	View FDMT research	View GYRE research